[EN] TETRAHYDRO-FURO`3,4-D!DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION [FR] COMPOSES TETRAHYDRO-FURO[3,4D]DIOXOLE, ET COMPOSITIONS ET PROCEDE POUR INHIBER UNE AGREGATION PLAQUETTAIRE
[EN] NON-NUCLEOTIDE COMPOSITIONS AND METHOD FOR TREATING PAIN<br/>[FR] COMPOSITIONS NON-NUCLEOTIDIQUES ET PROCEDE DE TRAITEMENT DE LA DOULEUR
申请人:INSPIRE PHARMACEUTICALS INC
公开号:WO2005039590A1
公开(公告)日:2005-05-06
The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.
Non-nucleotide composition and method for inhibiting platelet aggregation
申请人:Plourde, Robert
公开号:US20050267134A1
公开(公告)日:2005-12-01
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y
12
receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation, preferably in a reversible manner. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.
Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
申请人:Boyer L. Jose
公开号:US20060121086A1
公开(公告)日:2006-06-08
The present invention provides a drug-eluting stent, wherein the stent is coated with one or more non-mucleotide P2Y
12
receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y
12
receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y
12
receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
Non-nucleotide compositions and method for inhibiting platelet aggregation
申请人:Plourde Robert
公开号:US20050159388A1
公开(公告)日:2005-07-21
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y
12
receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formulae I and III-XI.
Non-nucleotide compositions and method for treating pain
申请人:Plourde Robert
公开号:US20070123544A1
公开(公告)日:2007-05-31
The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.